GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma Q2 FY27 Consolidated Revenue Up 29% to ₹964 Mn

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 28 Oct 2026, 06:48 PM IST  ·  BSE ID: 54551a4c-2c0d-4a66-9726-a79c750458fd
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's quarterly sales increased by 29% due to an acquisition, and its standalone profit for the half-year rose by 10.3%.
🤖 AI Summary
  • Jagsonpal Pharmaceuticals' Q2 FY27 consolidated revenue increased 29% to ₹964 Mn.
  • Standalone H1 FY27 net profit grew 10.3% to ₹258 Mn; EBITDA up 11.3% to ₹375 Mn.
  • Aequitas Healthcare (85% stake, ₹208 Mn all-cash) was consolidated from Q2 FY27.
  • Cash position was ₹1,347 Mn as of September 30, 2026, after a 200% dividend payout.
  • Standalone core business revenue rose 9.3% in Q2 FY27 and 9.0% in H1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q2 FY27 Consolidated Revenue
₹964 Mn
29%
Q2 FY27 Standalone Revenue
₹814 Mn
9.3%
Q2 FY27 Standalone PAT
₹126 Mn
0.1%
H1 FY27 Standalone Revenue
₹1,636 Mn
9.0%
H1 FY27 Standalone EBITDA
₹375 Mn
11.3%
H1 FY27 Standalone PAT
₹258 Mn
10.3%
Cash Position (Sep 30, 2026)
₹1,347 Mn
Aequitas Healthcare Acquisition Cost
₹208 Mn
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue growth of 29% to ₹964 Mn in Q2 FY27 is primarily driven by the consolidation of Aequitas Healthcare, which also opens the hospital channel with access to over 1,000 hospitals. The acquisition of Group Pharma Wellness Portfolio on October 1, 2026, strengthens the wellness segment and will contribute from Q3 FY27.
💰
Financial Impact
Standalone H1 FY27 net profit increased 10.3% to ₹258 Mn and EBITDA grew 11.3% to ₹375 Mn. The company maintains a strong cash position of ₹1,347 Mn as of September 30, 2026, despite a ₹208 Mn cash acquisition and a 200% dividend payout.
⚙️
Operational Impact
Investments in Q2 FY27 included strengthening the hospital team, appointing a new Aequitas business head, and marketing inputs for the Wellness portfolio. These initiatives are expected to reflect benefits from Q3 FY27.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with H1 FY27 standalone net profit increasing 10.3% to ₹258 Mn, indicating growth in profitability.
🔍
Management Signal
Management's strategy signals a focus on inorganic growth through acquisitions and front-ended investments to build future growth platforms, targeting ₹5,000 Mn revenue by 2028.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — verify if quarterly revenues cross ₹1,000 Mn.
Integration of Group Pharma Wellness Portfolio — assess its contribution from Q3 FY27.
Future acquisition announcements — monitor progress towards the ₹5,000 Mn revenue mission.
LOW RISK No specific risks or adverse events highlighted in the financial results.
💡 Investor Takeaway
Jagsonpal Pharmaceuticals reported Q2 FY27 consolidated revenue of ₹964 Mn, up 29%. Standalone H1 FY27 net profit increased 10.3% to ₹258 Mn, while standalone EBITDA grew 11.3% to ₹375 Mn. Cash reserves remained strong at ₹1,347 Mn as of September 30, 2026, after strategic acquisitions and dividend payouts.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue grew 29% in Q2 FY27 to ₹964 Mn, driven by both organic standalone growth and recent acquisitions.
  • Standalone H1 FY27 net profit increased 10.3% to ₹258 Mn with a robust cash position of ₹1,347 Mn.

⚠️ Concerns

  • Standalone EBITDA margin decreased by 151 bps in Q2 FY27 to 22.7%, attributed to investments for future growth.
  • Other Income for H1 FY27 decreased 13.5% to ₹51 Mn from ₹59 Mn in H1 FY26.
📅 Company Track Record
In Q1 FY27, Jagsonpal Pharmaceuticals reported a standalone net profit increase of 22.18% to Rs. 131.89 Million, with revenue at Rs. 822.32 Million. This current filing shows H1 FY27 standalone net profit growth at 10.3% to Rs. 258 Mn, indicating continued profitability.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Jagsonpal Pharmaceuticals' consolidated revenue in Q2 FY27?
Jagsonpal Pharmaceuticals reported a consolidated revenue of ₹964 Mn in Q2 FY27, representing a 29% growth year-on-year.
What was the standalone net profit for Jagsonpal Pharmaceuticals in H1 FY27?
The standalone net profit for Jagsonpal Pharmaceuticals in H1 FY27 was ₹258 Mn, showing a 10.3% increase year-on-year.
What is Jagsonpal Pharmaceuticals' cash position as of September 30, 2026?
As of September 30, 2026, Jagsonpal Pharmaceuticals had a strong cash position of ₹1,347 Mn.
Which acquisition was consolidated by Jagsonpal Pharmaceuticals in Q2 FY27?
Jagsonpal Pharmaceuticals consolidated Aequitas Healthcare (85% stake acquired for ₹208 Mn all-cash) from Q2 FY27.
What was the standalone revenue growth for Jagsonpal Pharmaceuticals in Q2 FY27?
The standalone revenue for Jagsonpal Pharmaceuticals grew 9.3% year-on-year to ₹814 Mn in Q2 FY27.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.